Related Experiment Video

Updated: Jul 10, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Trastuzumab for early breast cancer: current status and future directions

Phuong Dinh1, Evandro de Azambuja, Martine J Piccart-Gebhart

  • 1Breast European Adjuvant Study Team, Institut Jules Bordet, Université Libre de Bruxelles, 1000 Brussels, Belgium.

Clinical Advances in Hematology & Oncology : H&O
|November 6, 2007
PubMed

Insights

Trastuzumab significantly reduces recurrence and mortality in HER2-positive breast cancer. However, cardiotoxicity and cost are concerns, and further treatment options are needed for patients who relapse.

Area of Science:

  • Oncology
  • Translational Oncology
  • Breast Cancer Research

Background:

  • HER2 overexpression/amplification in 25% of breast cancers correlates with aggressive disease and poor survival.
  • Adjuvant chemotherapy was the primary treatment for HER2-positive breast cancer before targeted therapies.
  • Trastuzumab, a HER2-targeted antibody, has shown significant benefits in adjuvant settings.

Purpose of the Study:

  • To review the efficacy and safety of trastuzumab in five adjuvant breast cancer trials.
  • To evaluate the current clinical status of trastuzumab for HER2-positive breast cancer.
  • To explore future directions for treating HER2-positive breast cancers beyond trastuzumab.

Main Methods:

  • Systematic review of individual results from five adjuvant trastuzumab studies.
  • Analysis of efficacy and safety data, including recurrence rates and mortality.
  • Evaluation of clinical outcomes and financial implications of trastuzumab therapy.

Main Results:

  • Trastuzumab demonstrated a significant reduction in recurrence rates and mortality in HER2-positive early breast cancer.
  • The benefits of trastuzumab were consistent across multiple adjuvant trials.
  • Adverse events, including cardiotoxicity, and substantial financial costs are associated with trastuzumab treatment.

Conclusions:

  • Trastuzumab has revolutionized adjuvant treatment for HER2-positive breast cancer, substantially improving patient outcomes.
  • Despite its success, a significant proportion of patients still experience relapse, necessitating further therapeutic strategies.
  • Future research should focus on novel treatments and personalized approaches for HER2-positive breast cancers, considering resistance and toxicity.

More Related Videos

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.